Showing results (381-390 of 554) with videos related to
Sort By:
Pageof 56
Urologic Oncology|May 11, 2010
Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinomaAymen A Elfiky, Daniel C Cho, David F McDermott, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2015
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805Naomi B Haas, Judith Manola, Bonnie Ky, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|May 14, 2005
GLUT4 facilitative glucose transporter specifically and differentially contributes to agonist-induced vascular reactivity in mouse aortaJames L Park, Robert D Loberg, Damon Duquaine, et al.Oncotarget|June 2, 2016
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinomaXiaoen Wang, Nicolas Solban, Prateek Khanna, et al.ESMO Open|February 8, 2021
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆A A Tarhini, K Toor, K Chan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain MetastasesRavi K Amaravadi, Lynn M Schuchter, David F McDermott, et al.Oncotarget|February 4, 2017
The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanomaCynthia M Simbulan-Rosenthal, Sivanesan Dakshanamurthy, Anirudh Gaur, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2019
Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell CarcinomaWenxin Xu, Maneka Puligandla, Judith Manola, et al.ESMO Open|April 27, 2023
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinomaJ B A G Haanen, J Larkin, T K Choueiri, et al.Journal of the Endocrine Society|December 8, 2025
Differentiated Thyroid Cancer Is Associated With Sex-specific Immune ResponseLeila Shobab, Jennifer Simpson, Matthew McCoy, et al.Pageof 56